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ABSTRACT 
Background 
Current animal models of human cardiac disease may be similar in anatomy and 
physiology but are often expensive and tedious to work with. The current need is for a model 
organism that is more efficient to work with in the lab while still providing an accurate model of 
human cardiac disease. Drosophila melanogaster (D. mel) is such a candidate. While 74% of the 
genes coding for protein are conserved between D. mel and human hearts, it is unknown if 
cardiac medication used in humans, such as atropine and propranolol hydrochloride, similarly 
affect heart rate. I hypothesized that administration of atropine and propranolol hydrochloride 
to third instar larvae would cause an increase and decrease respectively in the heart rates of D. 
mel. 
Methods 
After larvae hatched and reached the second instar larval phase, they were moved to 
fresh vials. The control group larvae were transferred to vials containing no medication and the 
experimental group larvae were transferred to vials with 1mM atropine or 1mM propranolol 
hydrochloride. The larvae inhabited the new vials for 24 hours to reach the third instar larvae 
stage. Larvae were removed, placed individually on a microscope slide, and observed using the 
4X objective lens of a Leica compound microscope. Heart rates of 50 larvae per group were 
recorded in triplicate over 15 second intervals.  
Results 
We observed elevated heart rates of 406 ± 3.18 beats per minute in atropine treated 
larvae when compared to rates of 388 ± 2.07 in control larvae, a 4.83% increase. Moreover, 
heart rates were slowed to an average of 274 ± 2.70 beats per minute in propranolol 
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hydrochloride treated hearts, a 29.18% decrease. Both changes in heart rate when compared to 
the control were found to be statistically significant (p<0.001). 
Conclusion 
Administration of propranolol hydrochloride and atropine increased and decreased the 
heart rates of D. mel respectively. This data supports the hypothesis that D. mel can serve as an 
experimental model for human cardiovascular disease. Future work should build on this study 
and focus on the use of D. mel in preliminary pharmaceutical testing for new medication 
treating cardiovascular conditions. 
 
Keywords: drosophila menanogaster, atropine, propranolol hydrochloride, heart rate 
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INTRODUCTION 
Models of Cardiovascular Disease 
According to the American Heart Association, one American dies of cardiac disease 
every 40 seconds (Mozaffarian et al., 2015), and the causation, prevention, and treatment of 
cardiac disease are areas of active research. Organisms of mammalian origin are predominantly 
chosen for studying cardiac disease and include baboons, pigs, sheep, dogs, rabbits, rats, and 
mice (Hasenfuss, 1998). Mammals are typically used due to their similarity in physiology, making 
them candidates to research new treatment methods (Patel et al., 2001). Smaller mammals, 
such as rats and mice, are also useful because they can be genetically manipulated, and 
subsequently used to determine the effects of mutations in genes relating to cardiac function 
(Rosenthal & Brown, 2007).  Similarly, zebrafish have recently emerged as another model for 
human cardiac disease research and have been used to model congenital heart defects and 
cardiomyopathies, as well as to determine mechanisms that can lead to cardiac disease 
(Bakkers, 2011).  
These organisms have been pivotal in developing current knowledge regarding the 
physiology of the human cardiovascular system as well as the development and treatment of 
cardiovascular disease. Unfortunately, many of these organisms are inefficient to use in the 
laboratory. Costs to obtain and maintain these organisms in a laboratory setting are not trivial. 
According to the Jackson Laboratory website, purchasing mice for research would cost 
approximately $10.75 per mouse (“Jax mice pricing information”, 2018). Genetically modified 
mice are even more expensive, and according to the Cyagen Biosciences website, could range 
from $250 to nearly $7,000 depending on the desired method of inserting genes into the mouse 
genome (“Regular transgenic mice”, 2018). Rabbits, according to the Charles River website, 
range from $160 to $330 per rabbit depending on the weight (“New Zealand white rabbit”, 
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2018) . In addition, many of these animals can be difficult to handle and manage within the lab 
to ensure they are cared for humanely throughout research. Mice, for example, can move 
quickly and may attempt to bite the hands of researchers while handling (Buerge and Weiss, 
2004). Dogs and primates, according to the Johns Hopkins University Animal Care and Use 
Committee, may require tranquilization if they are aggressive and difficult to work with. To 
advance research in this area, it would be advantageous to find an organism that is more 
efficient to utilize in the lab while still providing an accurate model of human cardiac disease.  
Drosophila melanogaster 
D. mel is a candidate for modeling human cardiac disease and is an efficient organism to 
use in the lab for many reasons. One reason it is efficient is the well documented short lifespan 
of the organism (Linford et al., 2013). D. mel is used as a model of aging due to its short life span 
of approximately 50 days from fertilization of the egg to the death of the adult fly. This lifespan 
is significantly lower than those of typical mammals. A rat, for example, has an estimated mean 
life expectancy of 22 months (Baati et al., 2012). A shorter lifespan allows researchers to study 
organisms in different stages of life over a shorter amount of time.  
Another contributor to the efficiency of using D. mel is the immense research that has 
been done to sequence the genome of the organism (Pandey & Nichols, 2011). Scientists know 
many of the genes in the DNA of D. mel and are then able to use this information to determine 
whether genes code for disease or for resistance to disease. Further, D. mel can incur mutations 
in genes homologous to genes of human disease naturally or by manipulation (Bier & Bodmer, 
2004). This ability allows D. mel to be a model for discovering the outcome of mutations in 
genes necessary for physiological function and maintenance of health. 
Further benefits include the feasibility of raising the organisms in lab and the 
inexpensive cost (Doke & Dhawale, 2015). D. mel, in contrast to the prices of mammalian 
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models, can be purchased for $8.10 per vial containing 25 to 30 flies for moth wildtype and 
mutant strains. In addition, all of the materials necessary for culturing can be purchased for 
$65.50 (“Carolina easy fly drosophila cultures, living”, 2018).  
In addition to being a practical organism to work with, D. mel is a candidate for human 
cardiac disease research. A study performed by Cammarato et al. (2011) determined that the 
proteome, or complete protein makeup, of the D. mel heart contains 498 genes vital to heart 
function. 74 of these genes (15%) were protein products that are also produced in humans. 
Additionally, 73% of the genes were determined to be orthologs of genes found in humans and 
mice. Other experiments researching the genetic makeup of the D. mel heart have shown that 
they are physiologically similar to human hearts. The hearts of D. mel can develop structural 
defects and suffer from arrhythmias (irregular heartbeats) or cardiomyopathies (hereditary 
cardiac disease) (Pandey & Nichols, 2011). Another study used D. mel to model the development 
of age-related heart failure (Ocorr, Akasaka, & Bodmer, 2007). Due to genetic similarity, D. mel 
hearts develop heart failure caused by errors in pacing as well as arrhythmias, key factors in 
researching age-related heart failure. This research suggests that D. mel has a promising future 
in determining genetic contributions to cardiac disease. Anatomically, however, the heart of D. 
mel is different from that of a human (Figure 1).  
 
Figure 1 D. mel cardiac tube captured during the recording of 
heart rate. The image was taken of a D. mel larvae under the 4X 
objective lens of a Leica compound microscope. The outline of 
the head of the cardiac tube can be observed. Surrounding the 
cardiac tube is a single layer of cardiomyocytes. 
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In a study identifying the genetic components of heart development and function, it was 
noted that the D. mel heart has only one chamber, referred to as the cardiac tube, and lacks 
coronary arteries (Seyres, Röder, & Perrin, 2012). This structure is different than that of a 
human heart, in which there are four highly vascularized chambers. Another study notes that 
the D. mel heart has only one layer of cardiomyocytes (heart cells) whereas the human heart 
has two sections of cardiomyocytes, the myocardium and endocardium (Medioni et al., 2009). 
Despite the anatomical differences, though, the similarity in genetics and proteome present a 
convincing case for D. mel as a model of human cardiovascular disease.  
Despite current advances in understanding genomic similarities between D. mel and 
other organisms typically used as models, it is still not known whether the D. mel cardiovascular 
system is capable of responding similarly to heart medication. Understanding physiological 
responses of the D. mel heart to heart medication could further qualify it as a model of human 
cardiovascular disease and open new doors of research.  
Atropine 
Atropine is frequently prescribed to increase heart rate in instances of hypotension 
(“Atropine,” 2014). The drug is administered to those suffering from bradycardia, a condition of 
extremely low heart rate to increase firing of the SA node in the heart (Al, 2014). 
Atropine increases heart rate in humans by preventing acetylcholine from binding to 
sinoatrial and atrioventricular nodes. It does this by blocking muscarinic acetylcholine receptors 
(mAchRs) and, as a result, contraction of these pacemaking nodes increases (Kinkade, 2012). For 
this drug to effect D. mel in a similar fashion, the organism must have conserved receptors with 
the same capability of being blocked by atropine. One study determined which G-protein 
receptors in D. mel were coupled to mAchRs, the active site of atropine (Ren, Folke, Hauser, Li, 
& Grimmelikhuijzen, 2015). They found that mammals have five mAchRs and that D. mel has 
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only two, an A-type and B-type. Specifically, the A-type mAchRs in D. mel were determined to 
have a similar structure to the mammalian receptors. For these receptors to function similarly to 
human mAchRs, the D. mel heart would need to be similarly innervated. It was originally 
thought that the D. mel heart was not innervated. It was discovered, however, that the D. mel 
heart is indeed innervated (Dulcis & Levine, 2003). At the larval stage, heart rate is controlled by 
a pacemaker structure thought to be located in the caudal region of the heart. With all of this in 
mind, it is still not known whether these receptors can invoke the same response on the 
innervating structure of the D. mel heart. If the mAchRs of D. mel can respond to atropine 
similarly to humans, this would support our knowledge of D. mel as a model for human cardiac 
disease and medicinal research. 
Propranolol hydrochloride 
While the effect of atropine increases heart rate, propranolol hydrochloride is a β-
blocker that decreases heart rate and is prescribed by physicians for patients suffering from 
heart failure (Coppola, Froio, & Chiumello, 2015). Results of one study suggest that β-blockers 
benefit patients by reducing heart rate and thereby inducing relaxation which may have an 
effect on diastolic filling of the heart (Dobre et al., 2007).  
β-blockers reduce heart rate by blocking beta1-adrenergic receptors (βARs), reducing 
sinoatrial node automaticity and therefore heart rate (Gibson & Raphael, 2014). A study 
measuring the effects of βARs agonists versus antagonists on D. mel showed that antagonist β-
blockers, such as propranolol hydrochloride, decreased mortality by 6.4% (Spindler et al., 2013). 
The same study also showed that D. mel does not have βARs but possesses a family of G-protein 
receptors that are structurally and functionally related to βARs. However, it is not known 
whether treatment with propranolol produces an effect on heart rate. If the βAR-like receptors 
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in D. mel can respond to propranolol hydrochloride in a similar way to humans, this would 
further support D. mel as a model for human cardiac disease and medicinal research. 
The Effects of Heart Medication on D. mel 
While there is proteomic support for a conserved mechanism of regulation, it is 
unknown if heart medications such as atropine and propranolol hydrochloride have a similar 
effect on heart rate. We hypothesized that atropine and propranolol hydrochloride in the 
growth media of third instar larvae would cause an increase and decrease respectively in the 
heart rates of D. mel. Characterization of the pharmacologic activity of these two drugs on D. 
mel cardiac activity would further clarify if there are conserved mechanisms of heart rate 
regulation between the invertebrate D. mel and mammals and would lend further support to 
using D. mel as a model for human cardiac disease.   
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METHODS 
Materials and D. mel Culturing 
Wild type D. mel were purchased from Carolina Biological and atropine and propranolol 
hydrochloride were purchased from Sigma Aldrich. To maintain a constant living environment, 
the flies were kept at 22°C and transferred to new vials to mate. The vials were made by mixing 
equal amounts of Instant Drosophila Medium purchased from Carolina Biological with sterile 
deionized water in drosophila culturing vials with sponge plugs. The flies were given several days 
to lay eggs, and once larvae were seen in the vials, the adults were moved to new vials to repeat 
the process and obtain stock vials of adult flies. 
Treatment with Atropine and Propranolol Hydrochloride 
The experimental procedure required a time span of seven days to complete (Figure 2) 
and was completed three times in succession. On the first day, adult flies from stock vials were 
placed in three new vials to mate. Over the following four to five days, the adult flies laid eggs in 
the medium that hatched into larvae and began to mature. By the sixth day, the larvae reached 
the second instar larval phase. Larvae at this stage were preferred due to their burrowing nature 
in which they tunnel deep into their growth media, thereby increasing exposure to medication 
in the media. Second instar larvae were transferred to fresh vials that contained the 
experimental treatment. For the control group, 50 second instar larvae were moved to vials 
containing media made with sterile deionized water. For the first experimental group, 50 second 
instar larvae were transferred to vials with 1mM propranolol hydrochloride in the media. For 
the second experimental group, 50 second instar larvae were transferred to vials with 1mM 
atropine in the media. 1mM concentrations of each medication were utilized after performing a 
preliminary test of a tenfold range of molar concentrations, of which 1mM concentrations were 
found to display an effect on heart rate without mortality of the larvae. The second instar larvae 
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inhabited the new vials for twenty-four hours, maturing into third instar larvae during this time 
at which point heart rates were observed. 
 
Figure 2 Timeline of Procedure Detailing When Flies Were Moved to New Vials and When 
Heart Rates Were Recorded. On Day 1, adult flies were moved to new vials to mate. Over the 
next few days, the flies were left to lay eggs. Once the larvae hatched from the eggs and entered 
the second instar larval stage of development, they were moved to fresh media. At this stage, 
atropine or propranolol hydrochloride were administered to the media. After 24 hours, the third 
instar larval heart rates were recorded. 
Heart Rate Assessment of Third Instar Larvae 
The heart rate of each third instar larvae of the control and treatment groups was 
observed three times in 15 second intervals. Larvae were removed, placed individually on a 
microscope slide, and observed using the 4X objective lens of a Leica compound microscope. 
Beating hearts were visualized through the transparent skin of the dorsal side when larvae were 
placed on their ventral side. Once the microscope was properly focused on the larva, a 15 
second timer with a 10 second interval of rest was started. A tap counter was used to count the 
number of times the heart beat during each 15 second interval. After a 10 second rest, the 
process was repeated until a total of three heart rates had been recorded for the larva. 
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Values were averaged for each larva, with the resulting 50 averages used to calculate 
the average heart rate and standard error for the group. To determine the significance of the 
two experimental groups from the control group, a T-Test was performed. The statistical 
analysis was done using Microsoft Excel. 
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RESULTS 
 Second instar D. mel larvae were treated with 1mM atropine or 1mM propranolol 
hydrochloride for 24 hours, after which the heart rates of 50 larvae were assessed at the third 
instar larval stage for each treatment. These averages were compared to that of untreated 
control larvae (Figure 3). Atropine treatment resulted in a heart rate of 406 ± 3.18 beats per 
minute, which represented a 4.83% increase in heart rate over control hearts (388 ± 2.07 bpm). 
On the contrary, propranolol hydrochloride treated larvae had hearts rates of 275 ± 2.70 beats 
per minute, which was a 29.18% decrease in heart rate when compared to controls. Both 
changes in heart rate were statistically significant (p<0.001). These results indicate that both 
heart rate medications influenced a change in the heart rates of D. mel larvae. 
  
Figure 3 Atropine and Propranolol Hydrochloride act as respective positive and negative 
chrontropes of D. mel heart rates. Average heart rates of treated third instar larvae in the 
control, atropine (1mM), and propranolol hydrochloride (1mM) groups were assessed by 
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observing the heart rate using the 4X objective lens of a Leica compound microscope. Heart 
rates were recorded in triplicate for 50 in each group. Data are presented as mean plus and 
minus the standard error. Respective increase and decreases of heart rate due to atropine and 
propranolol hydrochloride treatments were statistically significant (p<0.001).   
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DISCUSSION 
 This research aimed to test whether D. mel larvae can respond similarly to humans 
when treated with heart medication. We observed a significant difference in the heart rates of 
the larvae that were treated with propranolol hydrochloride. Control larvae had an average 
heart rate of 388 ± 2.07 beats per minute while the propranolol hydrochloride treated larvae 
had an average heart rate of 275 ± 2.70 beats per minute (p<0.001).  This supports the 
hypothesis that propranolol hydrochloride decreases the heart rate of third instar larvae and 
demonstrates that D. mel responds to heart medication similarly as humans. Further, we also 
observed a difference in the heart rates of the larvae treated with atropine. Larvae treated with 
atropine had an increased heart rate of 406 ± 3.18 beats per minute (p<0.001). This supports the 
hypothesis that atropine increases the heart rate of third instar larvae and demonstrates that D. 
mel can respond to heart medication similarly as humans. 
 The effects of the two medications on the heart rates of D. mel support previous work 
that demonstrated the conserved mAchRs and βARs in D. mel. One study determined the 
protein content of the two mAchRs found in the D. mel genome (Ren et al., 2015). They 
concluded that one of the two mAchRs is pharmacologically similar to that of humans, however, 
they did not demonstrate that D. mel was capable of responding to atropine in a similar way to 
humans. The increase in heart rate due to atropine supports this research, further supporting 
the notion that the mAchRs in D. mel are pharmacologically similar to human mAchRs. Another 
study used propranolol hydrochloride to study the effects of β-blockers on the lifespan of D. mel 
(Spindler et al., 2013). In this research, it is explained that D. mel do not have the same βARs as 
humans, but rather utilize a family of G-protein receptors that may function very similarly to 
that of humans. The decrease in heart rate due to propranolol hydrochloride that was observed 
in this study would support this research and suggest that the heart of D. mel has conserved 
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receptors capable of responding to the β-blocker propranolol hydrochloride in a similar manner 
to humans. 
 To evaluate the similarity between the effects of atropine and propranolol on the heart 
rates of D. mel larvae and humans, it is necessary to compare the results of this experiment to 
those found by other studies. After the administration of atropine, there was an observed 4.83% 
increase in larval heart rate. One study, which measured heart rate after the endobronchial 
administration of atropine in humans, found a 16% increase in heart rate at a dosage of 0.02 
mg/kg (Paret et al., 1999). The difference between this 16% increase in heart rate from the 
observed 4.83% increase in heart rate is due to differences in atropine dose as well as the 
method of delivering the medication.  Another study found that atropine increased heart rate in 
humans by 13.1 beats per minute (bpm) after 80 minutes at a dosage of 0.15 µg/kg/min (Bruck, 
Ulrich, Gerlach, Radke, & Brodde, 2003). The difference between the 13.1 bpm increase from 
the approximately 18 bmp increase observed in this experiment is due to differences in dose.  
There was also an observed 29.18% increase in larval heart rate after the administration of 
propranolol hydrochloride. In one study, participants who received 40mg of propranolol 
hydrochloride were found to have resting heart rates of 62 bpm after five hours as opposed to 
72 bpm in participants who received the placebo (Joannides et al., 2006). The difference in 
recorded decrease in heart rate is due to the difference in dose administered and time between 
doses. Larvae in this experiment were exposed to propranolol hydrochloride for 24 hours before 
heart rate was recorded, however, participants in the study described above were exposed to 
the drug for only five hours. This difference in time could influence the observed decrease in 
heart rate in the two experiments. Through comparing the results of this experiment to those of 
other studies, it is apparent that the effects of the drugs on the heart rates of D. mel larvae are 
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similar. To confirm this conclusion, future studies need to employ concentrations of the drugs 
that more closely parallel those used in human studies. 
 There were limitations in the study design that should be recognized and improved 
upon in future research.  Most importantly, the research should have been completed as a 
blinded study. This would allow for experimental recording of heart rates while unaware of the 
group being observed. Performing the experiment in this way would eliminate the possibility of 
bias. Further, there are more precise methods of recording heart rate that could have been 
used. At heart rates as rapid as that of D. mel, human error in manually counting is inevitable. 
With additional funding, software could be purchased which would allow for computer-
generated analysis of videos of the beating larval heart that would more accurately assess the 
heart rate (Vogler & Ocorr, 2009). 
While further research will add to our knowledge in this area, the data collected in this 
experiment suggest that the D. mel heart responds to atropine and propranolol hydrochloride as 
the human heart does. If this is indeed the case, future research could be performed to discover 
whether D. mel has the capability of responding to other heart medications. In the future, D. mel 
could be used as a model organism for research being performed on the effects of these heart 
medications.  
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